Company intelligence / Profile preview

Raziel Therapeutics

Rehovot, Jerusalem District, Israelcdn.clinicaltrials.gov ↗

Ownership: Private
Development stage: Other

Overview

Raziel has developed RZL-012, a proprietary fat-dissolving injectable compound currently in Phase 3 trials in China for submental fat reduction. The company has completed earlier phase trials for localized obesity and Dercum's Disease.

Therapeutic areas: EndocrinologyRare DiseasesDermatology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

Tapencarium

Partnerships

Fosun Pharma (JuveStar) for Chinese market

Beyond the preview

Go deeper on Raziel Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Raziel Therapeutics.

Explore the full profile